Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (symbol: XAIR) is a clinical-stage medical device and biopharmaceutical company focused on revolutionizing respiratory disease treatments through innovative technology. The company's flagship product is the LungFit™ system, a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of both ventilated and non-ventilated patients. This breakthrough technology is aimed at treating various pulmonary diseases, including pulmonary hypertension, severe lung infections such as SARS-CoV-2, and nontuberculous mycobacteria (NTM).
LungFit™ can generate up to 400 ppm of NO, offering flexibility in delivery either continuously or for a fixed period. It also features the ability to titrate the dose on demand or maintain a constant dose. This system is currently advancing in clinical trials and has garnered attention for its potential in treating lower respiratory tract infections that are not effectively addressed by current standards of care.
Beyond Air is also exploring ultra-high concentrations of NO with a proprietary delivery system separate from LungFit™ to target certain solid tumors. This preclinical testing aims to offer new hope for cancer treatments, making Beyond Air a pioneer in utilizing NO for diverse therapeutic applications.
Notably, Beyond Air has achieved significant milestones, including FDA approval for its LungFit® PH system designed for treating term and near-term neonates with hypoxic respiratory failure. The company has partnered with The Hebrew University of Jerusalem to develop treatments for neurological disorders like autism spectrum disorder (ASD). In addition, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO to target specific solid tumors.
Financially, Beyond Air has shown a commitment to growth, as evidenced by its recent increase in general and administrative expenses, primarily driven by stock-based compensation and professional fees. The company maintains a forward-looking stance, aiming to expand its product portfolio and enhance its market position.
For more detailed information on their latest developments and product offerings, visit Beyond Air's official website.
Beyond Air, Inc. (NASDAQ: XAIR) has announced that CEO Steve Lisi will participate in two virtual investor conferences in March 2021. The conferences are the 33rd Annual Roth Conference, scheduled from March 15-17, and the Oppenheimer 31st Annual Healthcare Conference on March 16-18, with Lisi presenting on March 16 at 9:20 AM ET. Beyond Air focuses on developing inhaled nitric oxide treatments for serious lung infections and pulmonary hypertension, utilizing their innovative LungFit™ system.
Beyond Air, Inc. (NASDAQ: XAIR) has secured up to $2.17 million from the Cystic Fibrosis Foundation to advance its LungFit™ GO pilot study targeting Nontuberculous Mycobacteria (NTM) pulmonary disease. This 12-week trial in Australia aims to enroll around 20 patients suffering from refractory mycobacterial lung infections. Interim data is expected mid-2021, with topline results anticipated six months later. The funding will support the self-administration of high concentration nitric oxide (NO) for improved treatment outcomes, particularly for cystic fibrosis patients.
Beyond Air (NASDAQ: XAIR) announced its FDA is reviewing the premarket approval (PMA) for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN), potentially launching this summer. The company reported a revenue of $149,000 for Q3 2020, down from $314,000 in Q3 2019, with a net loss of $5.8 million, or ($0.33) per share. Their ongoing studies include acute viral pneumonia and Nontuberculous Mycobacteria treatments. Cash reserves stand at $22.7 million as of December 31, 2020. A conference call is scheduled for February 9th at 4:30 PM ET.
Beyond Air, Inc. (NASDAQ: XAIR) announces its financial results for the third fiscal quarter ending December 31, 2020. The report is scheduled for February 9, 2021, with a dedicated conference call at 4:30 PM ET. The company focuses on developing inhaled nitric oxide for various respiratory conditions and solid tumors, aiming to improve treatment options for severe lung infections like SARS-CoV-2. Beyond Air's innovative LungFit™ system delivers precise amounts of nitric oxide, targeting pulmonary diseases and advancing in clinical trials.
Beyond Air (NASDAQ: XAIR) has initiated a pilot clinical trial for its LungFit™ GO device targeting nontuberculous mycobacteria (NTM) lung disease, expected to enroll 20 adult patients in Australia. The 12-week, open-label study will first dose patients in January 2021 and report interim findings mid-2021. LungFit™ GO aims to provide at-home treatment options for patients with chronic respiratory conditions, potentially improving quality of life and outcomes for those with severe lung infections.
Beyond Air, Inc. (NASDAQ: XAIR) announced that Steve Lisi, its CEO, will participate in the 32nd Annual Piper Sandler Healthcare Conference virtually from December 1-3, 2020. The company will provide a pre-recorded investor presentation and engage in virtual one-on-one meetings.
Beyond Air is focused on developing inhaled nitric oxide (NO) therapies for respiratory conditions, including severe infections and pulmonary hypertension. Its LungFit™ device generates NO from ambient air, potentially treating various pulmonary diseases.
Beyond Air submitted a premarket approval (PMA) to the FDA for LungFit™ PH, targeting persistent pulmonary hypertension of the newborn (PPHN). Enrollment for an acute viral pneumonia study is set to begin next week. The company reported $350,000 in revenue for Q2 2020, down from $646,000 in Q2 2019, and a net loss of $5.1 million or ($0.30) per share. Cash reserves stand at $22.4 million. Upcoming milestones include potential FDA approval for LungFit™ PH and initiation of a pilot study for nontuberculous mycobacteria lung infection.
Beyond Air, Inc. (NASDAQ: XAIR) has submitted a premarket approval (PMA) application to the FDA for its LungFit™ PH device, aimed at treating persistent pulmonary hypertension of the newborn (PPHN). The PMA review will take 180 days, with a potential launch in Q2 2021 pending approval. This device generates nitric oxide from ambient air, eliminating the need for traditional gas cylinders, thereby enhancing safety and operational efficiency in hospitals. PPHN affects approximately 1.9 per 1000 live births and can have serious health consequences for newborns.
Beyond Air, Inc. (NASDAQ: XAIR) will report its financial results for the second fiscal quarter ended September 30, 2020, on November 11, 2020, followed by a conference call at 4:30 PM ET. The company focuses on developing inhaled nitric oxide for respiratory conditions and gaseous NO for treating tumors. Its product, LungFit™, can deliver precise NO dosage continuously or at fixed intervals, with ongoing clinical trials targeting severe lung infections, including SARS-CoV-2. For more information, visit www.beyondair.net.
Beyond Air, Inc. (NASDAQ: XAIR) announced plans to initiate a clinical study to evaluate the safety and efficacy of the LungFit™ system using inhaled Nitric Oxide (NO) for hospitalized adults with acute viral pneumonia, including SARS-CoV-2 infections. The multi-center trial in Israel aims to enroll 90 patients, comparing NO treatment combined with standard supportive care against supportive care alone. The LungFit™ system generates NO from ambient air, providing potential advantages in treating respiratory conditions.
FAQ
What is the current stock price of Beyond Air (XAIR)?
What is the market cap of Beyond Air (XAIR)?
What is Beyond Air, Inc.?
What is the LungFit™ system?
What diseases is Beyond Air targeting with LungFit™?
What recent achievements has Beyond Air made?
What other projects is Beyond Air involved in?
How does LungFit™ generate Nitric Oxide?
What are the financial conditions of Beyond Air?
Who has Beyond Air partnered with for research?
What kind of preclinical testing is Beyond Air conducting?
Where can I get more information about Beyond Air?
